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We report the clinical and molecular character-
istics of a 69-year-old woman with metastatic
colorectal cancer, treated with the epidermal
growth factor receptor (EGFR)-targeted mono-
clonal antibody panitumumab, displaying
peculiar molecular tumour heterogeneity at
progression consisting of KRAS and MET amp-
liﬁcation as distinct drivers associated with
acquired resistance.
The patient had rectosigmoid junction
adenocarcinoma, G3, KRAS (exon 2) wild
type, pT3N2(5/14)M0 treated with surgery in
March 2007 and then adjuvant capecitabine
(Xeloda) and oxaliplatin (XELOX) chemo-
therapy. In April 2009 the patient had pelvic
relapse and underwent presacral, paraortic
and inferior mesenteric lymphadenectomy
conﬁrming metastatic colon adenocarcin-
oma, KRAS (exon 2), BRAF and PIK3CA wild
type, human epidermal growth factor recep-
tor 2 (HER2) 2+ without ampliﬁcation by in
situ hybridisation1 and no ampliﬁcation of
KRAS or MET. The patient received subse-
quent chemotherapy for stage IV disease with
XELOX with progression and subsequently
FOLFIRI. At disease progression, based on
the RAS wild type status, on August 2010 the
patient started treatment with panitumumab,
achieving partial response which was main-
tained for 1 year. At that time disease pro-
gression occurred in the retroperitoneum,
abdominal lymph nodes, liver and lung. Since
the lymph nodes involvement caused ureteral
dilation and liver involvement was limited to a
single lesion in segment VII, in September
2011 the patient underwent surgery for exci-
sion of retroperitoneum and parailiac lymph
nodes and atypical liver resection of segment
VII. The histological diagnosis was consistent
with metastases of colon adenocarcinoma in
all three tumour metastatic sites.
Molecular assessment was performed on the
second metastasectomy and compared to data
of the previous one. Interestingly, a peculiar
intratumour heterogeneity was demonstrated,
as the liver metastasis was found to beMETamp-
liﬁed while KRAS was negative (ﬁgure 1A and
see online supplementary ﬁgure S1); con-
versely, in the retroperitoneum KRAS was ampli-
ﬁed whileMETwas negative (ﬁgure 1C and see
online supplementary ﬁgure S1). Finally, in the
ureteral metastatic deposit an ampliﬁcation of
both oncogenes was concomitantly present
(ﬁgure 1B and see online supplementary ﬁgure
S1). Overexpression of HER2 was not detected
in any of the metastatic sites analysed (data not
shown). This molecular status was different
from that demonstrated in the tumour speci-
mens of previous metastasectomy performed
before treatment with EGFR-targeted therapy,
where no ampliﬁcation of either KRAS or MET
was detected (data not shown).
We and others previously reported KRAS and
MET ampliﬁcations as bona ﬁde secondary resist-
ance mechanisms to pharmacological pressure
exerted by cetuximab or panitumumab.2–4 Here
we show that these molecular abnormalities can
simultaneously arise within the same patient
after initial response to treatment. Further, data
from this case study highlight how these distinct
genetic alterations can coexist in the same
tumour lesion but also might display substantial
intrapatient heterogeneity. In conclusion, this
molecular case study highlights how selective
drug pressure can sustain tumour evolution con-
sisting in the emergence of polyclonal mechan-
isms of resistance – within the same patient and
even within the same metastatic lesion–that
eventually drive cancer progression. The knowl-
edge of these coexisting molecular abnormal-
ities can inform targeted therapeutic strategies
to overcome drug resistance.5
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Figure 1 Immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) analysis of MET and KRAS. For IHC, the
specific MET antibody (Met (D1C2) XP Rabbit mAB, Cell Signaling Technology, Inc.; dilution 1:1000) and KRAS (F234)
antibody (SC-30, mouse monoclonal IgG2a Santa Cruz Biotechnology; dilution 1:100) have been used. For FISH analysis the
c-MET amplification probe (cytocell) and KRAS/CEN12q FISH probe (Abnova) have been used. Magnification for IHC pictures
is ×200 (scale bar: 100 µm), except for B2 that have ×40 (scale bar: 500 µm). Magnification for FISH pictures is ×630 (scale
bar: 10 µm). (A) Liver metastasis. (1) IHC showing cytoplasmic MET overexpression (red staining); (2) MET gene amplification
(red dots) by FISH in tumour nuclei; (3) IHC negative staining for KRAS protein expression in the same tumour area where MET
protein is overexpressed. (B) Ureteral metastasis. (1) IHC showing cytoplasmic MET overexpression (red staining) and FISH
analysis (inset) showing MET gene amplification; (2) dual-IHC assay showing overexpression of MET (red staining, upper left)
and KRAS (brown staining, bottom right) proteins in two different areas of the same specimen; (3) showing cytoplasmic and
membrane KRAS overexpression (red staining) and FISH analysis (inset) showing KRAS gene amplification in the tumour
nuclei. (C) Retroperitoneal metastasis. (1) IHC analysis showing negative staining for MET protein; (2) FISH analysis showing
KRAS gene amplification (red dots) in tumour nuclei; (3) IHC showing cytoplasmic and membrane KRAS overexpression (red
staining) in the same area where MET staining was negative.
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